Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies

Statistical Methods in Medical Research

Volumn 11, Issue 6, 2002, Pages 469-490

  O'Hagan, A ^a   Stevens, J W ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

ARTHRITIS; ASTHMA; BAYES THEOREM; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG DOSE REGIMEN; DRUG MEGADOSE; EXPERIMENTAL DESIGN; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART FAILURE; HUMAN; INFORMATION PROCESSING; LOW DRUG DOSE; METERED DOSE INHALER; METHODOLOGY; QUALITY ADJUSTED LIFE YEAR; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL CONCEPTS; STATISTICAL DISTRIBUTION; STATISTICAL MODEL; STATISTICAL PARAMETERS;

ARTHRITIS; ASTHMA; BAYES THEOREM; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; HEALTH SERVICES RESEARCH; HEART FAILURE, CONGESTIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 0036946477     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1191/0962280202sm305ra     Document Type: Review

References (69)

1. Australia Commonwealth Department of Human Services and Health. Interim document to accompany the guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: Including major submissions involving economic analysis. Canberra: Australia Government Publication Services, 2000 [online]. Available from http://www.health.gov.au/pbs/. Accessed 2002.
2. Canadian Coordinating Office for Health Technology Assessment. Guidelines for Economic Evaluation of Pharmaceuticals: Canada (2nd ed.). Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1997.
3. National Institute for Clinical Excellence. Technical guidance for manufacturers and sponsors [online]. Available from: http://www.nice.org.uk/. Accessed 2002.
4. Thompson SG, Barber JA. How should cost data in pragramatic randomised trials be analysed? British Medical Journal 2000; 320: 1197-1200.
5. O'Hagan A, Stevens JW. The probability of cost-effectiveness. BMC Medical Research Methodology 2002; 2: 5. (Published online at http://www.biomedcentral.com/1471-2288/2/5.)
6. Black WC. The CE plane: A graphic representation of cost-effectiveness. Medical Decision Making 1990; 10: 212-14.
7. Stinnett AA, Mullahy J. Net health benefits: A new framework for the analysis of uncertainity in cost-effectiveness analysis. Medical Decision Making 1998; 18(Suppl): S68-S80.
8. Cook JR, Glick HA, Gerth W, Kinosian B, Kotis JB. The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction. American Journal of Hypertension 1998; 11: 1433-41.
9. Raikou M, Gray A, Briggs A et al. Cost-effectiveness anaysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. British Medical Journal 1998; 317: 720-26.
10. Delaney BC, Wilson S, Roalfe A et al. Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: A randomised controlled trial in primary care. The Lancet 2000; 356: 1965-69.
11. Gray A, Raikou M, McGuire A et al. Cost-effectiveness analysis of an intensive blood glucose control policy in patients with type 2 diabetes: Economic analysis alongside randomised controlled trial (UKPDS 41). British Medical Journal 2000; 320: 1373-78.
12. Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, Delaney B. On behalf of the Dyspepsia Review Group. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. British Medical Journal 2000; 321: 659-64.
13. Sculpher MJ, Poole L, Cleland J et al. Low doses vs. high doses of the angiotensin coverting-enzyme inhibitor lisinopril in chronic heart failure: A cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival. (ATLAS). European Journal of Heart Failure 2000; 2: 447-54.
14. Jönsson B. Economics of drug treatment: For which patients is it cost-effective to lower cholesterol? The Lancet 2001; 358: 1251-56.
15. Neymark N, Adriaenssen, Gorlia T, Bolla M, Brochon D. Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: Results decisively determined by the cut-off time-point chosen for the analysis. European Journal of Cancer 2001; 37: 1768-74.
16. Van Hout BA, Al MJ, Gordon GS, Rutten FFH. Costs, effects and C/E-ratios alongside a clinical trial. Health Economics 1994; 3: 309-19.
17. Grieve AP. Issues for statisticians in pharmaco-economic evaluations. Statistics in Medicine 1998; 17: 1715-23.
18. O'Hagan A, Stevens JW, Montmartin J. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. PharmacoEconomics 2000; 17: 339-49.
19. Jones DA. A Bayesian approach to the economic evaluation of health care technologies. In Spiker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn. Philadelphia: Lippincott-Raven, 1996, pp. 1189-96.
20. Lilford RJ, Braunholtz D. The statistical basis of public policy: A paradigm shift is overdue. British Medical Journal 1996; 313: 603-607.
21. Lilford RJ, Braunholtz D. Who's afraid of Thomas Bayes? Journal of Epidemiology and Community Health 2000; 54: 731-39.
22. O'Brien BJ, Drummond MF, Labelle RJ, Willan A. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care. Medical Care 1994; 32: 150-63.
23. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Health Economics 1999; 8: 257-61.
24. Heitjan DF, Moskowitz AJ, Whang W. Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Economics 1999; 8: 191-201.
25. Wakker P, Klaassen MP. Confidence intervals for cost-effectiveness ratio. Health Economics 1995; 4: 373-81.
26. Willan AR, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: An application of Fieller's theorem. Health Economics 1996; 5: 297-305.
27. Laska EM, Meisner M, Siegel C. Statistical inference for cost-effectiveness ratios. Health Economics 1997; 6: 229-42.
28. Tambour M, Zethraeus N, Johannesson M. A note on confidence intervals in cos-effectiveness analysis. International Journal of Technology Assessment in Health Care 1998; 14: 467-71.
29. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Economics 1998; 7: 723-40.
30. O'Hagan A, Stevens JW, Montmartin J. Bayesian cost-effectiveness analysis from clinical trial data. Statistics in Medicine 2001; 20: 733-53.
31. Al MJ, Van Hout BA. A Bayesian approach to economic analysis of clinical trials: The case of stenting versus balloon angioplasty. Health Economics 2000; 9: 599-609.
32. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation. Health Economics 1997; 6: 327-40.
33. Briggs A, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. Journal of Health Service Research and Policy 1998; 3: 233-45.
34. Carpenter J, Bithell J. Bootstrap confidence intervals: Whe, which, what? A practical guide for medical statisticians. Statistics in Medicine 2000; 19: 1141-64.
35. Barber JA, Thompson SG. Analysis of cost data in randomized trials: An application of the nonparame tric bootstrap. Statitistics in Medicine 2000; 19: 2319-36.
36. O'Hagan A, Stevens JW. Assessing and comparing costs: How robust are the bootstrap and methods based on asymptomatic normality? Health Economics 2003; 12(1).
37. Cooper NJ, Sutton AJ, Mugford M, Abrams KR. Use of Bayesian Markov Chain Monte Carlo Methods to Model Cost-of-Illness Data. University of Leicester, 2002.
38. Cooper NJ, Mugford M, Barrett EM, Scott DGI, Symmons DPM. Economic impact if early inflammatory polyarthritis to the individual, health care service society: Preliminary results. Arthritis and Rheumatism (Supplement) 2000; 43(9): S143.
39. Chang B-H, Pocock S. Analyzing data with clumping at zero: An example demonstration. Journal of Clinical Epidemiology 2000; 53: 1036-43.
40. Pauwels RA, Hargreave FE, Camus P et al. A one-year comparison of Turbuhaler® versus pressurized metered-dose inhaler (pMDI) in asthmatic patients. Chest 1996; 110: 53-57.
41. O'Hagan A, Stevens JW. A framework for cost-effectiveness analysis from clinical trial data. Health Economics 2001; 10: 302-15.
42. Liljas B, Ståhl E, Pauwels RA. Cost-effectiveness analysis of a dry-powder inhaler (Turbuhaler®) versus a pressurized metered dose inhaler in patients with asthma. Pharmaco Economics 1997; 12: 267-77.
43. Neymark N, Adrianssen I, Gorlia T et al. Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: Results decisively determined by the cut-off time-point chosen for the analysis. European Journal of Cancer 2001; 37: 1768-74.
44. O'Hagan A. Bayesian Inference. London: Arnold, 1994: Chapter 10.
45. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics 1997; 53: 419-34.
46. Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika 2000; 87: 329-43.
47. Straderman RL. Estimating the mean of an increasing stochastic process at a censored stopping time. Journal of the American Statistical Association 2000; 95: 1192-1208.
48. Zhao H, Tian L. On estimating medical cost and incremental cost-effectiveness ratios with censored data. Biometrics 2001; 57: 1002-1008.
49. Heitjan DF. Bayesian interim analysis of Phase II cancer clinical trials. Statistics in Medicine 1997; 16: 1791-1802.
50. Kass RE, Greenhouse JB. Comments on 'Investigating therapies of potentially great benefit: ECMO' by JH Ware. Statistical Science 1989; 4: 310-17.
51. Kass RE, Wasserman L. The selection of prior distributions by formal rules. Journal of the American Statistical Association 1996; 91: 1343-70.
52. Kadane JB, Wolfson LJ. Experiences in elicitation. The Statistician 1998; 47: 3-19 (with discussion, 55-68).
53. O'Hagan A. Eliciting expert beliefs in substantial practical applications. The Statistician 1998; 47: 21-35 (with discussion, 55-68).
54. Parmar MKB, Spiegelhalter DJ, Freedman LS. The CHART trials: Bayesian design and monitoring in practice. Statistics in Medicine 1994; 13: 1297-1312.
55. Willan AR, O'Brien BJ. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. Health Economics 1999; 8: 203-11.
56. Gardiner JC, Huebner M, Jetton J, Bradley CJ. Power and sample size assessments for tests of hypotheses on cost-effectiveness ratios. Health Economics 2000; 9: 227-34.
57. Briggs A, Gray AM. Sample size and power calculations for stochastic cost-effectiveness analysis. Medical Decision Making 1998; 18: S81-S92.
58. Laska EM, Meisner M, Siegel C. Power and sample size in cost-effectiveness analysis. Medical Decision Making 1999; 19: 339-43.
59. Chaloner K, Verdinelli I. Bayesian experimental design: A review. Statistical Science 1995; 10: 273-304.
60. Lindley DV. The choice of sample size. The Statistician 1997; 46: 129-38.
61. Spiegelhalter DJ, Freedman LS. A predictive approach to selecting the size of a clinical trial, based of subjective clinical opinion. Statistics in Medicine 1986; 5: 1-13.
62. Hutton JL, Owens RG. Bayesian sample size calculations and prior beliefs about child sexual abuse. The Statistician 1993; 42: 399-404.
63. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Economics 1996; 5: 513-24.
64. Joseph L, Duberger R, Belisle P. Bayesian and mixed Bayesian/likehood criteria for sample size determination. Statistics in Medicine 1997; 16: 769-81.
65. Lee SJ, Zelen M. Clinical trials and sample size considerations: Another perspective. Statistical Science 2000; 15: 95-103.
66. O'Hagan A, Stevens JW. Bayesian assessment of sample size for clinical trials of cost-effectiveness. Medical Decision Making 2001; 21: 219-30.
67. Bayarri MJ, Berger JO. Quantifying surprise in the data and model verification (with discussion). In Bernardo JM et al. eds. Bayesian Statistics 6. Oxford: Oxford University Press, 1999, pp. 53-82.
68. Marshall EC, Spiegelhalter DJ. Simulation-based tests for divergent behaviour in hierarchial models. In submission to Biometrics, 2002.
69. O'Hagan A. HSSS model criticism. In Green PJ, Hjort NL and Richardson ST, eds. Highly Structured Stochastic Systems. Oxford: Oxford University Press, 2002.